BSXBOSTON SCIENTIFIC CORP
Surgical & Medical Instruments & Apparatus
- Revenue
- $20.1B
- 20% YoY
- Operating margin
- 18.0%
- 16% YoY
- EBITDA
- $5.0B
- 29% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 2.1×
- $10.4B net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyFired41% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $11.9B | $12.7B | $14.2B | $16.7B | $20.1B | 20% |
| Operating income | $1.2B | $1.6B | $2.3B | $2.6B | $3.6B | 39% |
| Operating cash flow | $1.9B | $1.5B | $2.5B | $3.4B | $4.5B | 32% |
| Capex | $554M | $588M | $711M | $790M | $876M | 11% |
| Stock-based comp | $194M | $220M | $233M | $266M | $299M | 12% |
| Buybacks | $0 | $0 | — | — | — | |
| Dividends | $55M | $55M | $28M | $0 | — |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.